Our findings revealed that high MET/ESR1 coexpression was associated with favorable clinicopathologic tumor features such as greater age at diagnosis, lower NPI scores, low-grade carcinoma, hormone receptor positivity, HER2-negative status, and luminal subtype. Here, ERBB2 is linked to carcinoma.